Journey Medical (DERM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 May, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of six directors for the upcoming term, with all nominees recommended by the board.
Proposal to ratify KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Board of directors and corporate governance
Six director nominees are presented for election, including Lindsay A. Rosenwald, M.D., Claude Maraoui, Neil Herskowitz, Justin Smith, Miranda Toledano, and Michael Pearce.
Audit committee and external auditor matters
KPMG LLP is proposed for ratification as the external auditor for the next fiscal year, with board recommendation in favor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Journey Medical
- Virtual meeting to elect directors, ratify auditor, and review governance and compensation.DERM
Proxy filing30 Apr 2026 - Emrosi™ drives revenue growth as a best-in-class rosacea therapy with rapid market adoption.DERMInvestor presentation30 Apr 2026
- EMROSI's launch drove 10% revenue growth, margin gains, and improved profitability in 2025.DERMQ4 202525 Mar 2026
- Q2 revenue $14.9M, positive EBITDA, DFD-29 FDA review ongoing, but going concern risks remain.DERMQ2 20241 Feb 2026
- FDA approves Emrosi for rosacea, launching in early 2025 with proven superiority to Oracea.DERMFDA Announcement17 Jan 2026
- Dermatology-focused pharma seeks $150M via flexible offerings amid ongoing losses and dilution risk.DERMRegistration Filing15 Jan 2026
- Emrosi FDA approval and launch set the stage for growth after a pivotal 2024.DERMQ4 202426 Dec 2025
- Emrosi launches in April with best-in-class efficacy, targeting rapid adoption and broad coverage.DERMStatus Update3 Dec 2025
- Virtual meeting to elect directors, ratify auditor, and approve officer exculpation amendment.DERMProxy Filing2 Dec 2025